Long3759.HKSep 2026
Pharmaron Beijing Co., Ltd.
Ariel expects Pharmaron to benefit from a broadening recovery in pharmaceutical outsourcing. Results exceeded expectations and management raised its full-year revenue outlook…
3759.HK
Which hedge funds are long 3759.HK?
4 published ideas on Pharmaron Beijing Co., Ltd. across 4 funds — 4 long and 0 short.
Pharmaron Beijing Co. hedge fund investment theses
Each stock pitch below comes from a fund manager's own investor letter, not a 13F filing, so it carries the reasoning behind the portfolio position on Pharmaron Beijing Co.: the full investment thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.
Funds with a position view
Long theses
Long3759.HKSep 2026
Pharmaron Beijing Co., Ltd.
Pharmaron beat earnings expectations and raised its full-year revenue forecast on strong orders in laboratory services, drug development and clinical research. Continued contract…
Long3759.HKJun 2026
Pharmaron Beijing Co., Ltd.
Pharmaron is positioned to benefit from China's growing role in global biopharma innovation. Its integrated discovery, development and manufacturing platform lets it participate…
Long3759.HKJun 2026
Pharmaron Beijing Co., Ltd.
Ariel expects Pharmaron to benefit from China's growing role in global biopharma innovation and the increasing externalization of drug discovery and development by large…